Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7970149rdf:typepubmed:Citationlld:pubmed
pubmed-article:7970149lifeskim:mentionsumls-concept:C0007806lld:lifeskim
pubmed-article:7970149lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:7970149lifeskim:mentionsumls-concept:C0077589lld:lifeskim
pubmed-article:7970149pubmed:issue1lld:pubmed
pubmed-article:7970149pubmed:dateCreated1994-12-7lld:pubmed
pubmed-article:7970149pubmed:abstractTextTyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2), an endogenous brain peptide, was incubated at 37 degrees C in cerebrospinal fluid (CSF) from rats and the amount remaining in intact from determined by high performance liquid chromatography (HPLC). By 3 min, a time at which Tyr-MIF-1 had been considerably degraded by rat plasma, essentially no degradation of the tetrapeptide had occurred in CSF. Tyr-MIF-1 persisted in mainly intact form for the 8 days tested, with a calculated half-time degradation of 11.4 days. The simultaneous addition to CSF of equal amounts of Tyr-MIF-1 tritiated on the Tyr and Tyr-MIF-1 tritiated on the Pro facilitated determination of whether Tyr-MIF-1 serves as a precursor of MIF-1 (Pro-Leu-Gly-NH2) in CSF. This possibility was excluded by the findings that the primary metabolite was Tyr-Pro, with minimal and equal amounts of the free amino acids Pro and Tyr being formed, but no MIF-1. The results show the extreme stability of Tyr-MIF-1 in CSF and are consistent with a role for this peptide in the CNS.lld:pubmed
pubmed-article:7970149pubmed:languageenglld:pubmed
pubmed-article:7970149pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7970149pubmed:citationSubsetIMlld:pubmed
pubmed-article:7970149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7970149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7970149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7970149pubmed:statusMEDLINElld:pubmed
pubmed-article:7970149pubmed:monthJunlld:pubmed
pubmed-article:7970149pubmed:issn0304-3940lld:pubmed
pubmed-article:7970149pubmed:authorpubmed-author:KastinA JAJlld:pubmed
pubmed-article:7970149pubmed:authorpubmed-author:BanksW AWAlld:pubmed
pubmed-article:7970149pubmed:authorpubmed-author:HahnKKlld:pubmed
pubmed-article:7970149pubmed:authorpubmed-author:ZadinaJ EJElld:pubmed
pubmed-article:7970149pubmed:issnTypePrintlld:pubmed
pubmed-article:7970149pubmed:day6lld:pubmed
pubmed-article:7970149pubmed:volume174lld:pubmed
pubmed-article:7970149pubmed:ownerNLMlld:pubmed
pubmed-article:7970149pubmed:authorsCompleteYlld:pubmed
pubmed-article:7970149pubmed:pagination26-8lld:pubmed
pubmed-article:7970149pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:meshHeadingpubmed-meshheading:7970149-...lld:pubmed
pubmed-article:7970149pubmed:year1994lld:pubmed
pubmed-article:7970149pubmed:articleTitleExtreme stability of Tyr-MIF-1 in CSF.lld:pubmed
pubmed-article:7970149pubmed:affiliationVA Medical Center, New Orleans, LA.lld:pubmed
pubmed-article:7970149pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7970149pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7970149lld:pubmed